AGM 2019 Presentation

November 26, 2019August 16, 2022 Alterity Therapeutics

2019

Post navigation

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
Alterity Therapeutics Raises A$40.0 million in Placement
Alterity Therapeutics Announces Funding to Accelerate ATH434 Clinical and Business Development Activities
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

AGM 2019 Presentation

Related Posts

EMA publishes minutes recommending Orphan Drug Designation for PBT2

ANA NLP Poster

Metal Hypothesis for Alzheimer’s, Huntington and other Neurodegenerative Diseases Declared Promising Therapeutic Strategy by Scientists at New York Academy of Sciences Symposium